Inventor
RUI LINGYUN
US36 patents
⚠️ This page may combine multiple inventors who share the name “RUI LINGYUN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMUNOGEN INC
23 patentsUS9670279B2Jun 6, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC26 citations98
US9133275B2Sep 15, 2015
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC45 citations98
US10752683B2Aug 25, 2020
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC13 citations94
US10301385B2May 28, 2019
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC8 citations92
US10077313B2Sep 18, 2018
Anti-CD123 antibodies and conjugates and derivatives thereof
IMMUNOGEN INC12 citations92
US10017578B2Jul 10, 2018
Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies
IMMUNOGEN INC12 citations92
US9670278B2Jun 6, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC18 citations92
US9670280B2Jun 6, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC19 citations92
US9657100B2May 23, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC16 citations92
US9637547B2May 2, 2017
Monoclonal antibodies for detection of folate receptor 1
IMMUNOGEN INC15 citations92
US9598490B2Mar 21, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC18 citations92
US9346887B2May 24, 2016
CD37-binding molecules and immunoconjugates thereof
IMMUNOGEN INC12 citations92
US10919969B2Feb 16, 2021
Anti-CD123 antibodies and conjugates and derivatives thereof
IMMUNOGEN INC4 citations83
US10544230B2Jan 28, 2020
Methods of using antibodies to detect folate receptor 1 (FOLR1)
IMMUNOGEN INC4 citations83
US10442865B2Oct 15, 2019
Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof
IMMUNOGEN INC4 citations83
US11198736B2Dec 14, 2021
Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody
IMMUNOGEN INC5 citations81
US11932701B2Mar 19, 2024
Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate
IMMUNOGEN INC1 citations72
US11332535B2May 17, 2022
Anti-CD123 antibodies and conjugates and derivatives thereof
IMMUNOGEN INC2 citations72
US10875925B2Dec 29, 2020
Anti-CD123 antibodies and conjugates and derivatives thereof
IMMUNOGEN INC3 citations72
US11897961B2Feb 13, 2024
Anti-CD123 antibodies and conjugates and derivatives thereof
IMMUNOGEN INC0 citations62
US9125896B2Sep 8, 2015
EGFR-binding molecules and immunoconjugates thereof
IMMUNOGEN INC3 citations62
US11732038B2Aug 22, 2023
Conjugates comprising cell-binding agents and cytotoxic agents
IMMUNOGEN INC0 citations60
US10988531B2Apr 27, 2021
Conjugates comprising cell-binding agents and cytotoxic agents
IMMUNOGEN INC1 citations60
DEBIOPHARM INT SA
4 patentsUS11466095B2Oct 11, 2022
CD37-binding molecules and immunoconjugates thereof
DEBIOPHARM INT SA3 citations83
US10202460B2Feb 12, 2019
CD37-binding molecules and immunoconjugates thereof
DEBIOPHARM INT SA7 citations83
US11104740B2Aug 31, 2021
Antibodies and assays for detection of CD37
DEBIOPHARM INT SA2 citations67
US12559566B2Feb 24, 2026
CD37-binding molecules immunoconjugates thereof
DEBIOPHARM INT SA0 citations62
CUGENE INC
4 patentsUS11634467B2Apr 25, 2023
Cytokine-based bioactivatable drugs and methods of uses thereof
CUGENE INC3 citations71
US12319722B2Jun 3, 2025
Interleukin-15 (IL-15) fusion proteins and uses thereof
CUGENE INC0 citations61
US12319723B2Jun 3, 2025
Cytokine-based bioactivatable drugs and methods of uses thereof
CUGENE INC0 citations61
US12152060B2Nov 26, 2024
Interleukin-2 variants and methods of uses thereof
CUGENE INC1 citations61